Kemin Industries, a global ingredient manufacturer based in Des Moines, announced today that it has signed an exclusive agreement with Pacific GeneTech, a biologics company that develops and commercializes next-generation vaccines for areas of high unmet or underserved needs in food safety and animal health, to license PGT's salmonella vaccine for poultry. PGT's salmonella vaccine was developed from the company's proprietary Aegis platform, which is applicable to multiple pathogens, including bacteria, parasites and viruses. "Partnering with PGT on this vaccine will allow Kemin to deliver the technology needed to address salmonella contamination in poultry, a common pathogen that threatens food safety and the health of consumers," said Chris Nelson, Kemin’s president and CEO. As part of its partnership with PGT, Kemin will focus on developing the salmonella vaccine and registering it in the United States and other countries, beginning with the European Union. Kemin will also begin expanding the vaccine's availability in Southeast Asia and Africa.